Pharma & Healthcare
Global Antiangiogenic Drugs Market Outlook, In‑Depth Analysis & Forecast to 2031
- Nov 04, 25
- ID: 560333
- Pages: 160
- Figures: 163
- Views: 1
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Antiangiogenic Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Bayer
Sanofi
Eli Lilly
Roche
Pfizer
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
AstraZeneca
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Simcere
Segment by Type
Macromolecular Single-target Angiogenesis Inhibitor
Small Molecule Multi-target Angiogenesis Inhibitor
Endogenous Pan-target Angiogenesis Inhibitor
Segment by Application
Cancer Therapy
Ophthalmic Diseases
Inflammatory and Autoimmune Diseases
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Antiangiogenic Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Antiangiogenic Drugs market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Bayer
Sanofi
Eli Lilly
Roche
Pfizer
Jiangsu Hengrui Pharmaceuticals
Chia Tai Tianqing
Novartis
AstraZeneca
Exelixis
Boehringer Ingelheim
Eisai
Janssen Biotech
Simcere
Segment by Type
Macromolecular Single-target Angiogenesis Inhibitor
Small Molecule Multi-target Angiogenesis Inhibitor
Endogenous Pan-target Angiogenesis Inhibitor
Segment by Application
Cancer Therapy
Ophthalmic Diseases
Inflammatory and Autoimmune Diseases
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
India
Europe
Germany
France
U.K.
Italy
Russia
Central South America
Brazil
Argentina
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Antiangiogenic Drugs study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
1 Study Coverage
1.1 Introduction to Antiangiogenic Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Antiangiogenic Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Macromolecular Single-target Angiogenesis Inhibitor
1.2.3 Small Molecule Multi-target Angiogenesis Inhibitor
1.2.4 Endogenous Pan-target Angiogenesis Inhibitor
1.3 Market Segmentation by Application
1.3.1 Global Antiangiogenic Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Inflammatory and Autoimmune Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antiangiogenic Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Antiangiogenic Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Antiangiogenic Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Antiangiogenic Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Antiangiogenic Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Antiangiogenic Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Macromolecular Single-target Angiogenesis Inhibitor Market Size by Manufacturers
3.5.2 Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Manufacturers
3.5.3 Endogenous Pan-target Angiogenesis Inhibitor Market Size by Manufacturers
3.6 Global Antiangiogenic Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Antiangiogenic Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Antiangiogenic Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Antiangiogenic Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Antiangiogenic Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Antiangiogenic Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Antiangiogenic Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Antiangiogenic Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Antiangiogenic Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Antiangiogenic Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Business Overview
11.1.3 Bayer Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.1.4 Bayer Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Bayer Antiangiogenic Drugs Sales by Product in 2024
11.1.6 Bayer Antiangiogenic Drugs Sales by Application in 2024
11.1.7 Bayer Antiangiogenic Drugs Sales by Geographic Area in 2024
11.1.8 Bayer Antiangiogenic Drugs SWOT Analysis
11.1.9 Bayer Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.2.4 Sanofi Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Antiangiogenic Drugs Sales by Product in 2024
11.2.6 Sanofi Antiangiogenic Drugs Sales by Application in 2024
11.2.7 Sanofi Antiangiogenic Drugs Sales by Geographic Area in 2024
11.2.8 Sanofi Antiangiogenic Drugs SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.3.4 Eli Lilly Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Eli Lilly Antiangiogenic Drugs Sales by Product in 2024
11.3.6 Eli Lilly Antiangiogenic Drugs Sales by Application in 2024
11.3.7 Eli Lilly Antiangiogenic Drugs Sales by Geographic Area in 2024
11.3.8 Eli Lilly Antiangiogenic Drugs SWOT Analysis
11.3.9 Eli Lilly Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Business Overview
11.4.3 Roche Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.4.4 Roche Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Roche Antiangiogenic Drugs Sales by Product in 2024
11.4.6 Roche Antiangiogenic Drugs Sales by Application in 2024
11.4.7 Roche Antiangiogenic Drugs Sales by Geographic Area in 2024
11.4.8 Roche Antiangiogenic Drugs SWOT Analysis
11.4.9 Roche Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.5.4 Pfizer Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Antiangiogenic Drugs Sales by Product in 2024
11.5.6 Pfizer Antiangiogenic Drugs Sales by Application in 2024
11.5.7 Pfizer Antiangiogenic Drugs Sales by Geographic Area in 2024
11.5.8 Pfizer Antiangiogenic Drugs SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.6.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.6.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Corporation Information
11.7.2 Chia Tai Tianqing Business Overview
11.7.3 Chia Tai Tianqing Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.7.4 Chia Tai Tianqing Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Chia Tai Tianqing Recent Developments
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Business Overview
11.8.3 Novartis Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.8.4 Novartis Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Novartis Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Corporation Information
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.9.4 AstraZeneca Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 AstraZeneca Recent Developments
11.10 Exelixis
11.10.1 Exelixis Corporation Information
11.10.2 Exelixis Business Overview
11.10.3 Exelixis Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.10.4 Exelixis Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Exelixis Recent Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Corporation Information
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.11.4 Boehringer Ingelheim Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Boehringer Ingelheim Recent Developments
11.12 Eisai
11.12.1 Eisai Corporation Information
11.12.2 Eisai Business Overview
11.12.3 Eisai Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.12.4 Eisai Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Eisai Recent Developments
11.13 Janssen Biotech
11.13.1 Janssen Biotech Corporation Information
11.13.2 Janssen Biotech Business Overview
11.13.3 Janssen Biotech Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.13.4 Janssen Biotech Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Janssen Biotech Recent Developments
11.14 Simcere
11.14.1 Simcere Corporation Information
11.14.2 Simcere Business Overview
11.14.3 Simcere Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.14.4 Simcere Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Simcere Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Antiangiogenic Drugs Industry Chain
12.2 Antiangiogenic Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Antiangiogenic Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Antiangiogenic Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Antiangiogenic Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Antiangiogenic Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
1.1 Introduction to Antiangiogenic Drugs: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Antiangiogenic Drugs Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Macromolecular Single-target Angiogenesis Inhibitor
1.2.3 Small Molecule Multi-target Angiogenesis Inhibitor
1.2.4 Endogenous Pan-target Angiogenesis Inhibitor
1.3 Market Segmentation by Application
1.3.1 Global Antiangiogenic Drugs Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Cancer Therapy
1.3.3 Ophthalmic Diseases
1.3.4 Inflammatory and Autoimmune Diseases
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Antiangiogenic Drugs Revenue Estimates and Forecasts 2020-2031
2.2 Global Antiangiogenic Drugs Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Antiangiogenic Drugs Sales Estimates and Forecasts 2020-2031
2.4 Global Antiangiogenic Drugs Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Antiangiogenic Drugs Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Antiangiogenic Drugs Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Macromolecular Single-target Angiogenesis Inhibitor Market Size by Manufacturers
3.5.2 Small Molecule Multi-target Angiogenesis Inhibitor Market Size by Manufacturers
3.5.3 Endogenous Pan-target Angiogenesis Inhibitor Market Size by Manufacturers
3.6 Global Antiangiogenic Drugs Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Antiangiogenic Drugs Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Antiangiogenic Drugs Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Antiangiogenic Drugs Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Antiangiogenic Drugs Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
6.4 North America Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Antiangiogenic Drugs Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
7.4 Europe Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Antiangiogenic Drugs Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Antiangiogenic Drugs Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
9.4 Central and South America Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Antiangiogenic Drugs Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Antiangiogenic Drugs Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Antiangiogenic Drugs Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Antiangiogenic Drugs Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Bayer
11.1.1 Bayer Corporation Information
11.1.2 Bayer Business Overview
11.1.3 Bayer Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.1.4 Bayer Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Bayer Antiangiogenic Drugs Sales by Product in 2024
11.1.6 Bayer Antiangiogenic Drugs Sales by Application in 2024
11.1.7 Bayer Antiangiogenic Drugs Sales by Geographic Area in 2024
11.1.8 Bayer Antiangiogenic Drugs SWOT Analysis
11.1.9 Bayer Recent Developments
11.2 Sanofi
11.2.1 Sanofi Corporation Information
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.2.4 Sanofi Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Sanofi Antiangiogenic Drugs Sales by Product in 2024
11.2.6 Sanofi Antiangiogenic Drugs Sales by Application in 2024
11.2.7 Sanofi Antiangiogenic Drugs Sales by Geographic Area in 2024
11.2.8 Sanofi Antiangiogenic Drugs SWOT Analysis
11.2.9 Sanofi Recent Developments
11.3 Eli Lilly
11.3.1 Eli Lilly Corporation Information
11.3.2 Eli Lilly Business Overview
11.3.3 Eli Lilly Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.3.4 Eli Lilly Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Eli Lilly Antiangiogenic Drugs Sales by Product in 2024
11.3.6 Eli Lilly Antiangiogenic Drugs Sales by Application in 2024
11.3.7 Eli Lilly Antiangiogenic Drugs Sales by Geographic Area in 2024
11.3.8 Eli Lilly Antiangiogenic Drugs SWOT Analysis
11.3.9 Eli Lilly Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Business Overview
11.4.3 Roche Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.4.4 Roche Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Roche Antiangiogenic Drugs Sales by Product in 2024
11.4.6 Roche Antiangiogenic Drugs Sales by Application in 2024
11.4.7 Roche Antiangiogenic Drugs Sales by Geographic Area in 2024
11.4.8 Roche Antiangiogenic Drugs SWOT Analysis
11.4.9 Roche Recent Developments
11.5 Pfizer
11.5.1 Pfizer Corporation Information
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.5.4 Pfizer Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Pfizer Antiangiogenic Drugs Sales by Product in 2024
11.5.6 Pfizer Antiangiogenic Drugs Sales by Application in 2024
11.5.7 Pfizer Antiangiogenic Drugs Sales by Geographic Area in 2024
11.5.8 Pfizer Antiangiogenic Drugs SWOT Analysis
11.5.9 Pfizer Recent Developments
11.6 Jiangsu Hengrui Pharmaceuticals
11.6.1 Jiangsu Hengrui Pharmaceuticals Corporation Information
11.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
11.6.3 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.6.4 Jiangsu Hengrui Pharmaceuticals Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
11.7 Chia Tai Tianqing
11.7.1 Chia Tai Tianqing Corporation Information
11.7.2 Chia Tai Tianqing Business Overview
11.7.3 Chia Tai Tianqing Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.7.4 Chia Tai Tianqing Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Chia Tai Tianqing Recent Developments
11.8 Novartis
11.8.1 Novartis Corporation Information
11.8.2 Novartis Business Overview
11.8.3 Novartis Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.8.4 Novartis Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Novartis Recent Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Corporation Information
11.9.2 AstraZeneca Business Overview
11.9.3 AstraZeneca Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.9.4 AstraZeneca Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.9.5 AstraZeneca Recent Developments
11.10 Exelixis
11.10.1 Exelixis Corporation Information
11.10.2 Exelixis Business Overview
11.10.3 Exelixis Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.10.4 Exelixis Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.10.5 Exelixis Recent Developments
11.11 Boehringer Ingelheim
11.11.1 Boehringer Ingelheim Corporation Information
11.11.2 Boehringer Ingelheim Business Overview
11.11.3 Boehringer Ingelheim Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.11.4 Boehringer Ingelheim Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.11.5 Boehringer Ingelheim Recent Developments
11.12 Eisai
11.12.1 Eisai Corporation Information
11.12.2 Eisai Business Overview
11.12.3 Eisai Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.12.4 Eisai Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.12.5 Eisai Recent Developments
11.13 Janssen Biotech
11.13.1 Janssen Biotech Corporation Information
11.13.2 Janssen Biotech Business Overview
11.13.3 Janssen Biotech Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.13.4 Janssen Biotech Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.13.5 Janssen Biotech Recent Developments
11.14 Simcere
11.14.1 Simcere Corporation Information
11.14.2 Simcere Business Overview
11.14.3 Simcere Antiangiogenic Drugs Product Models, Descriptions and Specifications
11.14.4 Simcere Antiangiogenic Drugs Sales, Price, Revenue and Gross Margin (2020-2025)
11.14.5 Simcere Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Antiangiogenic Drugs Industry Chain
12.2 Antiangiogenic Drugs Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Antiangiogenic Drugs Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Antiangiogenic Drugs Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Antiangiogenic Drugs Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Antiangiogenic Drugs Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
List of Tables
Table 1. Global Antiangiogenic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Antiangiogenic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Antiangiogenic Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Antiangiogenic Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Antiangiogenic Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Antiangiogenic Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Antiangiogenic Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Antiangiogenic Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Antiangiogenic Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Antiangiogenic Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Antiangiogenic Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antiangiogenic Drugs as of 2024)
Table 16. Global Antiangiogenic Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Antiangiogenic Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Antiangiogenic Drugs Manufacturing Base and Headquarters
Table 19. Global Antiangiogenic Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Antiangiogenic Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Antiangiogenic Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Antiangiogenic Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Antiangiogenic Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Antiangiogenic Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Antiangiogenic Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Antiangiogenic Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Antiangiogenic Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Antiangiogenic Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Antiangiogenic Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Antiangiogenic Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Antiangiogenic Drugs Growth Accelerators and Market Barriers
Table 37. North America Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Antiangiogenic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Antiangiogenic Drugs Growth Accelerators and Market Barriers
Table 40. Europe Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Antiangiogenic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Antiangiogenic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Antiangiogenic Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Antiangiogenic Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Antiangiogenic Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Bayer Corporation Information
Table 51. Bayer Description and Major Businesses
Table 52. Bayer Product Models, Descriptions and Specifications
Table 53. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Bayer Sales Value Proportion by Product in 2024
Table 55. Bayer Sales Value Proportion by Application in 2024
Table 56. Bayer Sales Value Proportion by Geographic Area in 2024
Table 57. Bayer Antiangiogenic Drugs SWOT Analysis
Table 58. Bayer Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Antiangiogenic Drugs SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Eli Lilly Corporation Information
Table 69. Eli Lilly Description and Major Businesses
Table 70. Eli Lilly Product Models, Descriptions and Specifications
Table 71. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Eli Lilly Sales Value Proportion by Product in 2024
Table 73. Eli Lilly Sales Value Proportion by Application in 2024
Table 74. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 75. Eli Lilly Antiangiogenic Drugs SWOT Analysis
Table 76. Eli Lilly Recent Developments
Table 77. Roche Corporation Information
Table 78. Roche Description and Major Businesses
Table 79. Roche Product Models, Descriptions and Specifications
Table 80. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Roche Sales Value Proportion by Product in 2024
Table 82. Roche Sales Value Proportion by Application in 2024
Table 83. Roche Sales Value Proportion by Geographic Area in 2024
Table 84. Roche Antiangiogenic Drugs SWOT Analysis
Table 85. Roche Recent Developments
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Product Models, Descriptions and Specifications
Table 89. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Pfizer Sales Value Proportion by Product in 2024
Table 91. Pfizer Sales Value Proportion by Application in 2024
Table 92. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 93. Pfizer Antiangiogenic Drugs SWOT Analysis
Table 94. Pfizer Recent Developments
Table 95. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 96. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 97. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 100. Chia Tai Tianqing Corporation Information
Table 101. Chia Tai Tianqing Description and Major Businesses
Table 102. Chia Tai Tianqing Product Models, Descriptions and Specifications
Table 103. Chia Tai Tianqing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Chia Tai Tianqing Recent Developments
Table 105. Novartis Corporation Information
Table 106. Novartis Description and Major Businesses
Table 107. Novartis Product Models, Descriptions and Specifications
Table 108. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Novartis Recent Developments
Table 110. AstraZeneca Corporation Information
Table 111. AstraZeneca Description and Major Businesses
Table 112. AstraZeneca Product Models, Descriptions and Specifications
Table 113. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. AstraZeneca Recent Developments
Table 115. Exelixis Corporation Information
Table 116. Exelixis Description and Major Businesses
Table 117. Exelixis Product Models, Descriptions and Specifications
Table 118. Exelixis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Exelixis Recent Developments
Table 120. Boehringer Ingelheim Corporation Information
Table 121. Boehringer Ingelheim Description and Major Businesses
Table 122. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 123. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Boehringer Ingelheim Recent Developments
Table 125. Eisai Corporation Information
Table 126. Eisai Description and Major Businesses
Table 127. Eisai Product Models, Descriptions and Specifications
Table 128. Eisai Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Eisai Recent Developments
Table 130. Janssen Biotech Corporation Information
Table 131. Janssen Biotech Description and Major Businesses
Table 132. Janssen Biotech Product Models, Descriptions and Specifications
Table 133. Janssen Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Janssen Biotech Recent Developments
Table 135. Simcere Corporation Information
Table 136. Simcere Description and Major Businesses
Table 137. Simcere Product Models, Descriptions and Specifications
Table 138. Simcere Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Simcere Recent Developments
Table 140. Key Raw Materials Distribution
Table 141. Raw Materials Key Suppliers
Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 143. Milestones in Production Technology Evolution
Table 144. Distributors List
Table 145. Market Trends and Market Evolution
Table 146. Market Drivers and Opportunities
Table 147. Market Challenges, Risks, and Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Antiangiogenic Drugs Product Picture
Figure 2. Global Antiangiogenic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Macromolecular Single-target Angiogenesis Inhibitor Product Picture
Figure 4. Small Molecule Multi-target Angiogenesis Inhibitor Product Picture
Figure 5. Endogenous Pan-target Angiogenesis Inhibitor Product Picture
Figure 6. Global Antiangiogenic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Cancer Therapy
Figure 8. Ophthalmic Diseases
Figure 9. Inflammatory and Autoimmune Diseases
Figure 10. Other
Figure 11. Antiangiogenic Drugs Report Years Considered
Figure 12. Global Antiangiogenic Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 14. Global Antiangiogenic Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Antiangiogenic Drugs Revenue Market Share by Region (2020-2031)
Figure 16. Global Antiangiogenic Drugs Sales (2020-2031) & (K Units)
Figure 17. Global Antiangiogenic Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Antiangiogenic Drugs Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Antiangiogenic Drugs Sales Volume Market Share in 2024
Figure 20. Global Antiangiogenic Drugs Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 23. Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 24. Endogenous Pan-target Angiogenesis Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 25. Global Antiangiogenic Drugs Sales Market Share by Type (2020-2031)
Figure 26. Global Antiangiogenic Drugs Revenue Market Share by Type (2020-2031)
Figure 27. Global Antiangiogenic Drugs Sales Market Share by Application (2020-2031)
Figure 28. Global Antiangiogenic Drugs Revenue Market Share by Application (2020-2031)
Figure 29. North America Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 30. North America Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 32. North America Antiangiogenic Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 33. North America Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 35. North America Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 40. Europe Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 42. Europe Antiangiogenic Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 43. Europe Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 45. Europe Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. France Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 52. Asia-Pacific Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Antiangiogenic Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 55. Asia-Pacific Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 57. Asia-Pacific Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. India Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 64. Central and South America Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Antiangiogenic Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 67. Central and South America Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 69. Central and South America Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 73. Middle East and Africa Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Antiangiogenic Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 76. South America Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 78. Middle East and Africa Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 83. Antiangiogenic Drugs Industry Chain Mapping
Figure 84. Regional Antiangiogenic Drugs Manufacturing Base Distribution (%)
Figure 85. Global Antiangiogenic Drugs Production Market Share by Region (2020-2031)
Figure 86. Antiangiogenic Drugs Production Process
Figure 87. Regional Antiangiogenic Drugs Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
Table 1. Global Antiangiogenic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Antiangiogenic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Antiangiogenic Drugs Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Antiangiogenic Drugs Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Antiangiogenic Drugs Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Antiangiogenic Drugs Sales by Region (2020-2025) & (K Units)
Table 8. Global Antiangiogenic Drugs Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Antiangiogenic Drugs Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Antiangiogenic Drugs Sales Share by Manufacturers (2020-2025)
Table 12. Global Antiangiogenic Drugs Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Antiangiogenic Drugs Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Antiangiogenic Drugs by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antiangiogenic Drugs as of 2024)
Table 16. Global Antiangiogenic Drugs Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Antiangiogenic Drugs Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Antiangiogenic Drugs Manufacturing Base and Headquarters
Table 19. Global Antiangiogenic Drugs Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Antiangiogenic Drugs Sales by Type (2020-2025) & (K Units)
Table 23. Global Antiangiogenic Drugs Sales by Type (2026-2031) & (K Units)
Table 24. Global Antiangiogenic Drugs Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Antiangiogenic Drugs Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Antiangiogenic Drugs ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Antiangiogenic Drugs Sales by Application (2020-2025) & (K Units)
Table 29. Global Antiangiogenic Drugs Sales by Application (2026-2031) & (K Units)
Table 30. Antiangiogenic Drugs High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Antiangiogenic Drugs Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Antiangiogenic Drugs Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Antiangiogenic Drugs ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Antiangiogenic Drugs Growth Accelerators and Market Barriers
Table 37. North America Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Antiangiogenic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Antiangiogenic Drugs Growth Accelerators and Market Barriers
Table 40. Europe Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Antiangiogenic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Antiangiogenic Drugs Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Antiangiogenic Drugs Growth Accelerators and Market Barriers
Table 45. Southeast Asia Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Antiangiogenic Drugs Investment Opportunities and Key Challenges
Table 47. Central and South America Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Antiangiogenic Drugs Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Antiangiogenic Drugs Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Bayer Corporation Information
Table 51. Bayer Description and Major Businesses
Table 52. Bayer Product Models, Descriptions and Specifications
Table 53. Bayer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Bayer Sales Value Proportion by Product in 2024
Table 55. Bayer Sales Value Proportion by Application in 2024
Table 56. Bayer Sales Value Proportion by Geographic Area in 2024
Table 57. Bayer Antiangiogenic Drugs SWOT Analysis
Table 58. Bayer Recent Developments
Table 59. Sanofi Corporation Information
Table 60. Sanofi Description and Major Businesses
Table 61. Sanofi Product Models, Descriptions and Specifications
Table 62. Sanofi Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. Sanofi Sales Value Proportion by Product in 2024
Table 64. Sanofi Sales Value Proportion by Application in 2024
Table 65. Sanofi Sales Value Proportion by Geographic Area in 2024
Table 66. Sanofi Antiangiogenic Drugs SWOT Analysis
Table 67. Sanofi Recent Developments
Table 68. Eli Lilly Corporation Information
Table 69. Eli Lilly Description and Major Businesses
Table 70. Eli Lilly Product Models, Descriptions and Specifications
Table 71. Eli Lilly Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Eli Lilly Sales Value Proportion by Product in 2024
Table 73. Eli Lilly Sales Value Proportion by Application in 2024
Table 74. Eli Lilly Sales Value Proportion by Geographic Area in 2024
Table 75. Eli Lilly Antiangiogenic Drugs SWOT Analysis
Table 76. Eli Lilly Recent Developments
Table 77. Roche Corporation Information
Table 78. Roche Description and Major Businesses
Table 79. Roche Product Models, Descriptions and Specifications
Table 80. Roche Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Roche Sales Value Proportion by Product in 2024
Table 82. Roche Sales Value Proportion by Application in 2024
Table 83. Roche Sales Value Proportion by Geographic Area in 2024
Table 84. Roche Antiangiogenic Drugs SWOT Analysis
Table 85. Roche Recent Developments
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer Product Models, Descriptions and Specifications
Table 89. Pfizer Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Pfizer Sales Value Proportion by Product in 2024
Table 91. Pfizer Sales Value Proportion by Application in 2024
Table 92. Pfizer Sales Value Proportion by Geographic Area in 2024
Table 93. Pfizer Antiangiogenic Drugs SWOT Analysis
Table 94. Pfizer Recent Developments
Table 95. Jiangsu Hengrui Pharmaceuticals Corporation Information
Table 96. Jiangsu Hengrui Pharmaceuticals Description and Major Businesses
Table 97. Jiangsu Hengrui Pharmaceuticals Product Models, Descriptions and Specifications
Table 98. Jiangsu Hengrui Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Jiangsu Hengrui Pharmaceuticals Recent Developments
Table 100. Chia Tai Tianqing Corporation Information
Table 101. Chia Tai Tianqing Description and Major Businesses
Table 102. Chia Tai Tianqing Product Models, Descriptions and Specifications
Table 103. Chia Tai Tianqing Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Chia Tai Tianqing Recent Developments
Table 105. Novartis Corporation Information
Table 106. Novartis Description and Major Businesses
Table 107. Novartis Product Models, Descriptions and Specifications
Table 108. Novartis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Novartis Recent Developments
Table 110. AstraZeneca Corporation Information
Table 111. AstraZeneca Description and Major Businesses
Table 112. AstraZeneca Product Models, Descriptions and Specifications
Table 113. AstraZeneca Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 114. AstraZeneca Recent Developments
Table 115. Exelixis Corporation Information
Table 116. Exelixis Description and Major Businesses
Table 117. Exelixis Product Models, Descriptions and Specifications
Table 118. Exelixis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 119. Exelixis Recent Developments
Table 120. Boehringer Ingelheim Corporation Information
Table 121. Boehringer Ingelheim Description and Major Businesses
Table 122. Boehringer Ingelheim Product Models, Descriptions and Specifications
Table 123. Boehringer Ingelheim Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 124. Boehringer Ingelheim Recent Developments
Table 125. Eisai Corporation Information
Table 126. Eisai Description and Major Businesses
Table 127. Eisai Product Models, Descriptions and Specifications
Table 128. Eisai Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 129. Eisai Recent Developments
Table 130. Janssen Biotech Corporation Information
Table 131. Janssen Biotech Description and Major Businesses
Table 132. Janssen Biotech Product Models, Descriptions and Specifications
Table 133. Janssen Biotech Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 134. Janssen Biotech Recent Developments
Table 135. Simcere Corporation Information
Table 136. Simcere Description and Major Businesses
Table 137. Simcere Product Models, Descriptions and Specifications
Table 138. Simcere Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 139. Simcere Recent Developments
Table 140. Key Raw Materials Distribution
Table 141. Raw Materials Key Suppliers
Table 142. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 143. Milestones in Production Technology Evolution
Table 144. Distributors List
Table 145. Market Trends and Market Evolution
Table 146. Market Drivers and Opportunities
Table 147. Market Challenges, Risks, and Restraints
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Antiangiogenic Drugs Product Picture
Figure 2. Global Antiangiogenic Drugs Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Macromolecular Single-target Angiogenesis Inhibitor Product Picture
Figure 4. Small Molecule Multi-target Angiogenesis Inhibitor Product Picture
Figure 5. Endogenous Pan-target Angiogenesis Inhibitor Product Picture
Figure 6. Global Antiangiogenic Drugs Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 7. Cancer Therapy
Figure 8. Ophthalmic Diseases
Figure 9. Inflammatory and Autoimmune Diseases
Figure 10. Other
Figure 11. Antiangiogenic Drugs Report Years Considered
Figure 12. Global Antiangiogenic Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 13. Global Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 14. Global Antiangiogenic Drugs Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 15. Global Antiangiogenic Drugs Revenue Market Share by Region (2020-2031)
Figure 16. Global Antiangiogenic Drugs Sales (2020-2031) & (K Units)
Figure 17. Global Antiangiogenic Drugs Sales (CAGR) by Region (2020-2031) (K Units)
Figure 18. Global Antiangiogenic Drugs Sales Market Share by Region (2020-2031)
Figure 19. Top 5 and Top 10 Manufacturers Antiangiogenic Drugs Sales Volume Market Share in 2024
Figure 20. Global Antiangiogenic Drugs Revenue Market Share Ranking (2024)
Figure 21. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 22. Macromolecular Single-target Angiogenesis Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 23. Small Molecule Multi-target Angiogenesis Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 24. Endogenous Pan-target Angiogenesis Inhibitor Revenue Market Share by Manufacturer in 2024
Figure 25. Global Antiangiogenic Drugs Sales Market Share by Type (2020-2031)
Figure 26. Global Antiangiogenic Drugs Revenue Market Share by Type (2020-2031)
Figure 27. Global Antiangiogenic Drugs Sales Market Share by Application (2020-2031)
Figure 28. Global Antiangiogenic Drugs Revenue Market Share by Application (2020-2031)
Figure 29. North America Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 30. North America Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 32. North America Antiangiogenic Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 33. North America Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 35. North America Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 40. Europe Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 42. Europe Antiangiogenic Drugs Sales Volume (K Units) by Type (2020-2031)
Figure 43. Europe Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 45. Europe Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 47. France Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 52. Asia-Pacific Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Antiangiogenic Drugs Sales Volume (K Units) by Type (2020- 2031)
Figure 55. Asia-Pacific Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 57. Asia-Pacific Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 62. India Antiangiogenic Drugs Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 64. Central and South America Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Antiangiogenic Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 67. Central and South America Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 69. Central and South America Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Antiangiogenic Drugs Sales YoY (2020-2031) & (K Units)
Figure 73. Middle East and Africa Antiangiogenic Drugs Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Antiangiogenic Drugs Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Antiangiogenic Drugs Sales Volume (K Units) by Type (2021-2031)
Figure 76. South America Antiangiogenic Drugs Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Antiangiogenic Drugs Sales Volume (K Units) by Application (2020-2031)
Figure 78. Middle East and Africa Antiangiogenic Drugs Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Antiangiogenic Drugs Revenue (2020-2025) & (US$ Million)
Figure 83. Antiangiogenic Drugs Industry Chain Mapping
Figure 84. Regional Antiangiogenic Drugs Manufacturing Base Distribution (%)
Figure 85. Global Antiangiogenic Drugs Production Market Share by Region (2020-2031)
Figure 86. Antiangiogenic Drugs Production Process
Figure 87. Regional Antiangiogenic Drugs Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global UV Delayed Curing Adhesives Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Die-Casting Die Steel Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Global Adaptive Neuromodulation Therapy Devices Market Outlook, In‑Depth Analysis & Forecast to 2031
Nov 04, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232